Aerovate Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Net Income	-75.52	-51.51	-22.96	-9.61	-3.33
Depreciation & Amortization	0.1	0.07	0.02	0	0
Share-Based Compensation	11.91	5.48	2.04	0.06	0
Other Operating Activities	6.74	6.85	-6.49	1.69	0.55
Operating Cash Flow	-56.78	-39.12	-27.4	-7.86	-2.78
Capital Expenditures	-0.14	-0.2	-0.18	0	0
Change in Investments	12.02	7.12	-113.25	0	0
Investing Cash Flow	11.88	6.93	-113.43	0	0
Share Issuance / Repurchase	46.23	0.77	126.95	0.01	0
Debt Issued / Paid	0	0	0	2.5	2.5
Other Financing Activities	-0.23	-0.37	63.51	6.41	-
Financing Cash Flow	46	0.4	190.46	8.92	2.5
Net Cash Flow	1.09	-31.8	49.62	1.06	-0.28
Free Cash Flow	-56.92	-39.32	-27.58	-7.86	-2.78
Free Cash Flow Per Share	-2.16	-1.61	-2.24	-32.44	-3.71

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).